Skip to search formSkip to main contentSkip to account menu

PRIMA-1 Analog APR-246

Known as: PRIMA-1MET 
A methylated derivative and structural analog of PRIMA-1 (p53 re-activation and induction of massive apoptosis), with potential antineoplastic… 
National Institutes of Health

Related topics

Related topics

2 relations

Narrower (1)

APR-246
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
PRIMA-1MET Induces Cellular Senescence and Apoptotic Cell Death in Cholangiocarcinoma Cells
Background/Aim: This study examined the in vitro effects of the bile duct cancer drug PRIMA-1MET on cholangiocarcinoma (CCA) cell… 
2016
2016
miRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc
The proto-oncogene c-Myc plays substantial role in multiple myeloma (MM) pathogenesis and is considered a potential drug target… 
2016
2016
Abstract 270: Synergistic effect with APR-246 and standard chemotherapy in small cell lung cancer cells carrying smoking-associated TP53 mutations
Background: Although smoking increases risk for many tumor types, no malignancy is more closely linked to tobacco exposure than… 
2015
2015
PRIMA-1MET (APR-246): A novel targeted therapy for triple negative breast cancer?
e12072 Background: Despite intensive efforts, a validated targeted therapy for triple-negative breast cancer (TNBC) remains… 
2015
2015
Prima-1Met Combined with Bortezomib Has Synergistic Anti-Myeloma Activity By Modulation of Apoptosis and Cell Cycle Regulating Genes
INTRODUCTION Multiple Myeloma (MM) is a plasma-cell malignancy characterized by dismal prognosis and a high level of relapse… 
2015
2015
Abstract 2523: Strong synergistic effects with APR-246 and cisplatin in p53-mutant lung cancer cells
Background: Platinum compounds have been used as first-line treatment for many solid tumors including non small cell (NSCLC) and… 
2014
2014
Abstract 1801: APR-246, a clinical-stage mutant p53-reactivating compound, resensitizes ovarian cancer cells to platinum compounds and doxorubicin
Background: Platinum-based drugs are since decades used as first-line treatment for many solid tumors. Patients with ovarian… 
2014
2014
Studi Dinamika Molekuler Mekanisme Reaktivasi p53 (Tumor Supresor) Termutasi dengan PRIMA-1
Apoptosis, kematian sel terprogram merupakan target yang menjanjikan untuk rekayasa obat kemoterapi yang spesifik. Reaktivasi… 
2010
2010
PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells.
2008
2008
PRIMA-1Met induces mitochondrial apoptosis through activation of caspase-2
p53 mutations occur frequently in human tumors. The low-molecular-weight compound PRIMA-1MET reactivates mutant p53, induces… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)